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background:  Bivalirudin compared with heparin has been shown to reduce rates of bleeding and death in patients undergoing primary 
percutaneous coronary intervention (PCI). In light of recent literature showing the opposite, the aim of the current study is to compare the 
acute outcomes and cost in a contemporary population of patients undergoing PCI.
methods:  Prospective data from 1/1/11 till 3/31/13 at 2 tertiary care centers in the New York area was obtained. Univariate, bivariate 
and propensity score adjusted analyses were performed. The primary endpoint was acute adverse outcome (composite of bleeding and 
transfusion). The secondary one was cost effectiveness.
Results:  Among the 6,719 PCI patients (5,510 bivalirudin) heparin monotherapy patients were younger, more often males, Asian, 
Hispanic, with lower insurance coverage, and sicker presentation compared to bivalirudin. There were no statistically significant differences 
in outcomes (composite and individual) between heparin and bivalirudin (OR 1.08, p=0.748; OR 1.06, p=0.867; OR 1.00, p=0.993 
respectively), including after propensity score adjustment. A cost analysis showed a potential for a per annum cost reduction of USD 2.7M 
by replacing bivalirudin with heparin (Table).
conclusion:  In an all comer PCI population there were no statistically significant differences in outcomes but a significant cost reduction in 
using heparin instead of bivalirudin. Accordingly, a heparin monotherapy approach should be strongly considered in PCI.
 
